US3051621A
(en)
*
|
1959-10-22 |
1962-08-28 |
Grove Lab Inc |
Gel composition, pressurized container with same, and method of preparation
|
US3050443A
(en)
*
|
1960-02-16 |
1962-08-21 |
James F Schuyler |
Headache remedy containing ammonia
|
NL262354A
(es)
*
|
1960-03-17 |
|
|
|
US3039928A
(en)
*
|
1960-03-17 |
1962-06-19 |
Abbott Lab |
Stable aqueous isoproteronol compositions
|
US3088874A
(en)
*
|
1960-05-23 |
1963-05-07 |
Union Carbide Corp |
Powder aerosol
|
US3282781A
(en)
*
|
1960-11-25 |
1966-11-01 |
Merck & Co Inc |
Inhalant compositions
|
BE632504A
(es)
*
|
1962-05-24 |
|
|
|
US3169095A
(en)
*
|
1962-10-30 |
1965-02-09 |
Rexall Drug Chemical |
Self-propelling powder-dispensing compositions
|
NL302251A
(es)
*
|
1963-01-28 |
1965-10-11 |
|
|
US3710782A
(en)
*
|
1969-10-01 |
1973-01-16 |
Hauser Res And Eng Co |
Method of treating human skin with a composition for electromedical applications
|
FI770215A
(es)
*
|
1976-01-30 |
1977-07-31 |
Fisons Ltd |
|
AU522792B2
(en)
*
|
1977-07-19 |
1982-06-24 |
Fisons Plc |
Pressure pack formulation
|
US4352789A
(en)
*
|
1980-03-17 |
1982-10-05 |
Minnesota Mining And Manufacturing Company |
Aerosol compositions containing finely divided solid materials
|
US4655231A
(en)
*
|
1984-01-09 |
1987-04-07 |
Advanced Tobacco Products, Inc. |
Snuff and preparation thereof
|
US4576949A
(en)
*
|
1984-05-07 |
1986-03-18 |
The Upjohn Company |
Use of 5,6,7,8-tetrahydroquinolines and 5,6-dihydropyrindines as leukotriene and lipoxygenase inhibitors and the novel 3-substituted compounds therein
|
EP0213108A3
(de)
*
|
1985-06-26 |
1987-07-15 |
Kurt Dr. Burghart |
Pharmazeutische Zubereitung mit einem Antihypotonikum als wirksames Mittel
|
JPH0645538B2
(ja)
*
|
1987-09-30 |
1994-06-15 |
日本化薬株式会社 |
ニトログリセリンスプレー剤
|
FR2625677A1
(fr)
*
|
1988-01-07 |
1989-07-13 |
Cosnier Alain |
Composition medicamenteuse destinee a etre administree sous forme d'aerosol
|
GB2216794B
(en)
*
|
1988-03-22 |
1991-11-20 |
Fisons Plc |
Pharmaceuticals compositions
|
US5766573A
(en)
*
|
1988-12-06 |
1998-06-16 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5225183A
(en)
*
|
1988-12-06 |
1993-07-06 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
US5439670A
(en)
*
|
1989-11-28 |
1995-08-08 |
Riker Laboratories, Inc. |
Medicinal aerosol formulations
|
DE4003270A1
(de)
*
|
1990-02-03 |
1991-08-08 |
Boehringer Ingelheim Kg |
Neue treibgase und ihre verwendung in arzneimittelzubereitungen
|
US5118494A
(en)
*
|
1990-03-23 |
1992-06-02 |
Minnesota Mining And Manufacturing Company |
Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations
|
US5175152A
(en)
*
|
1990-09-28 |
1992-12-29 |
Singh Nikhilesh N |
Composition containing ephedrine base and alkyl salicylate for the delivery of ephedrine base in vapor form
|
MX9203481A
(es)
|
1990-10-18 |
1992-07-01 |
Minnesota Mining & Mfg |
Formulaciones.
|
US5785952A
(en)
*
|
1990-11-09 |
1998-07-28 |
Glaxo Group Limited |
Aerosol medicament formulation having a surface coating of surfactant
|
US5919435A
(en)
|
1990-11-09 |
1999-07-06 |
Glaxo Group Limited |
Aerosol formulation containing a particulate medicament
|
ATE203900T1
(de)
|
1991-06-10 |
2001-08-15 |
Schering Corp |
Fluorchlorkohlenwasserstofffreie aerosolformulierungen
|
US5234933A
(en)
*
|
1991-10-31 |
1993-08-10 |
Board Of Governors Of Wayne State University And Vanderbilt University |
Cyclic hydroxamic acids
|
US5674471A
(en)
*
|
1991-12-12 |
1997-10-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and salbutamol
|
CA2421976C
(en)
*
|
1991-12-12 |
2004-04-20 |
Glaxo Group Limited |
Medicaments
|
US5744123A
(en)
*
|
1991-12-12 |
1998-04-28 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
US5658549A
(en)
*
|
1991-12-12 |
1997-08-19 |
Glaxo Group Limited |
Aerosol formulations containing propellant 134a and fluticasone propionate
|
US5916540A
(en)
*
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
EP0616525B1
(en)
*
|
1991-12-12 |
1995-09-27 |
Glaxo Group Limited |
Pharmaceutical aerosol formulation
|
US5736124A
(en)
*
|
1991-12-12 |
1998-04-07 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicament
|
IL104068A
(en)
*
|
1991-12-12 |
1998-10-30 |
Glaxo Group Ltd |
Pharmaceutical preparations in a spray without surfactant containing 1, 1, 1, 2 tetrafluoroethane or 1,1,2,3,3 petafluor N propane as propellant
|
US5653962A
(en)
*
|
1991-12-12 |
1997-08-05 |
Glaxo Group Limited |
Aerosol formulations containing P134a and particulate medicaments
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
DE69232034T2
(de)
*
|
1991-12-18 |
2002-06-06 |
Minnesota Mining And Mfg. Co., Saint Paul |
Aerosolzusammensetzungen für Arzneimittelsuspensionen
|
WO1994013262A1
(en)
*
|
1992-12-09 |
1994-06-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Stabilized medicinal aerosol solution formulations
|
ES2113574T3
(es)
*
|
1993-06-01 |
1998-05-01 |
Ono Pharmaceutical Co |
Derivados del acido pentanoico.
|
EP0640609A1
(en)
*
|
1993-08-24 |
1995-03-01 |
Ono Pharmaceutical Co., Ltd. |
Fused phenol derivatives having inhibitory activity on TXA2 synthetase, and 5-lipoxygenase and scavenging activity on oxygen species
|
DE69409471T2
(de)
*
|
1993-12-03 |
1998-08-27 |
Ono Pharmaceutical Co |
Amidinophenolderivate mit Phospholipase A2 inhibitorischer Wirkung
|
DK0735884T3
(da)
*
|
1993-12-20 |
2000-10-09 |
Minnesota Mining & Mfg |
Flunisolid-aerosolformuleringer
|
DK0703216T3
(da)
|
1994-09-20 |
1999-10-18 |
Ono Pharmaceutical Co |
Amidinophenolderivater som proteaseinhibitorer
|
US5840213A
(en)
*
|
1995-04-28 |
1998-11-24 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
US5679287A
(en)
*
|
1995-04-28 |
1997-10-21 |
Great Lakes Chemical Corporation |
Uses of heptafluoropropane
|
KR980009238A
(ko)
|
1995-07-28 |
1998-04-30 |
우에노 도시오 |
설포닐아미노산 유도체
|
DK0757984T3
(da)
*
|
1995-08-08 |
2003-03-03 |
Ono Pharmaceutical Co |
Hydroxamsyrederivater, der kan anvendes til inhibering af gelatinase
|
AUPN814496A0
(en)
*
|
1996-02-19 |
1996-03-14 |
Monash University |
Dermal penetration enhancer
|
US5861268A
(en)
*
|
1996-05-23 |
1999-01-19 |
Biomide Investment Limited Partnership |
Method for induction of tumor cell apoptosis with chemical inhibitors targeted to 12-lipoxygenase
|
US6054488A
(en)
*
|
1996-06-11 |
2000-04-25 |
3M Innovative Properties Company |
Medicinal aerosol formulations of formoterol
|
GB9616237D0
(en)
*
|
1996-08-01 |
1996-09-11 |
Norton Healthcare Ltd |
Aerosol formulations
|
CA2280099C
(en)
|
1997-02-05 |
2005-12-27 |
Jago Pharma Ag |
Medical aerosol formulations
|
US6129905A
(en)
*
|
1997-04-21 |
2000-10-10 |
Aeropharm Technology, Inc. |
Aerosol formulations containing a sugar as a dispersant
|
US5891420A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation
|
US5891419A
(en)
*
|
1997-04-21 |
1999-04-06 |
Aeropharm Technology Limited |
Environmentally safe flunisolide aerosol formulations for oral inhalation
|
US7153866B1
(en)
*
|
1997-05-27 |
2006-12-26 |
The United States Of America As Represented By The Department Of Health And Human Services |
Use of tempol for the treatment of Li-Fraumeni syndrome and ataxia telangiectasia
|
US20010031244A1
(en)
*
|
1997-06-13 |
2001-10-18 |
Chiesi Farmaceutici S.P.A. |
Pharmaceutical aerosol composition
|
JPH11187882A
(ja)
|
1997-12-26 |
1999-07-13 |
Ono Pharmaceut Co Ltd |
新規なポリペプチド、その製造方法、そのポリペプチドをコードするcDNA、そのcDNAからなるベクター、そのベクターで形質転換された宿主細胞、そのポリペプチドの抗体、およびそのペプチドまたは抗体を含有する薬学的組成物
|
WO2000006121A1
(de)
|
1998-07-24 |
2000-02-10 |
Jago Research Ag |
Medizinische aerosolformulierungen
|
US6475467B1
(en)
|
1998-08-04 |
2002-11-05 |
Jago Research Ag |
Medicinal aerosol formulations
|
US6136294C1
(en)
*
|
1998-09-22 |
2002-09-24 |
Aeropharm Technology Inc |
Amino acid stabilized medical aerosol formulation
|
US6458338B1
(en)
|
1998-09-22 |
2002-10-01 |
Aeropharm Technology Incorporated |
Amino acid stabilized medicinal aerosol formulations
|
DZ2947A1
(fr)
*
|
1998-11-25 |
2004-03-15 |
Chiesi Farma Spa |
Inhalateur à compteur de dose sous pression.
|
US6315985B1
(en)
*
|
1999-06-18 |
2001-11-13 |
3M Innovative Properties Company |
C-17/21 OH 20-ketosteroid solution aerosol products with enhanced chemical stability
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
KR100826866B1
(ko)
|
2001-07-23 |
2008-05-06 |
오노 야꾸힝 고교 가부시키가이샤 |
Ep4 아고니스트를 유효 성분으로 하는 골량 저하질환의 치료제
|
US7402580B2
(en)
|
2002-02-19 |
2008-07-22 |
Ono Pharmaceutical Co., Ltd. |
Fused pyridazine derivative compounds and drugs containing these compounds as the active ingredient
|
US7582284B2
(en)
*
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
US20050186141A1
(en)
*
|
2002-06-25 |
2005-08-25 |
Acrux Dds Pty Ltd. |
Transdermal aerosol compositions
|
US20050181032A1
(en)
*
|
2002-06-25 |
2005-08-18 |
Acrux Dds Pty Ltd. |
Metastable pharmaceutical compositions
|
NZ537360A
(en)
*
|
2002-06-25 |
2006-09-29 |
Acrux Dds Pty Ltd |
Transdermal delivery rate control using amorphous pharmaceutical compositions
|
PT1522314E
(pt)
|
2002-06-26 |
2014-06-05 |
Ono Pharmaceutical Co |
Medicamentos para doenças causadas pela contracção ou dilatação vascular
|
EP3287144A1
(en)
|
2002-07-03 |
2018-02-28 |
ONO Pharmaceutical Co., Ltd. |
Immunopotentiating compositions
|
TW200408393A
(en)
|
2002-10-03 |
2004-06-01 |
Ono Pharmaceutical Co |
Antagonist of lysophosphatidine acid receptor
|
US20060128810A1
(en)
*
|
2002-10-10 |
2006-06-15 |
Kyoto University |
Remedies for allergic diseases
|
DK1563846T3
(da)
|
2002-10-10 |
2012-12-17 |
Ono Pharmaceutical Co |
Endogene reparationsfaktorproduktionsfremmere
|
WO2004072286A1
(ja)
|
2003-01-23 |
2004-08-26 |
Ono Pharmaceutical Co., Ltd. |
ヒトpd−1に対し特異性を有する物質
|
RU2366655C2
(ru)
|
2003-03-14 |
2009-09-10 |
Оно Фармасьютикал Ко., Лтд. |
Азотсодержащие гетероциклические производные и лекарственные средства, содержащие их в качестве активного ингредиента
|
EP1619193A4
(en)
|
2003-04-18 |
2010-08-11 |
Ono Pharmaceutical Co |
SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF
|
EP1624866A2
(en)
*
|
2003-05-16 |
2006-02-15 |
Arriva Pharmaceuticals, Inc. |
Treatment of respiratory disease by inhalation of synthetic matrix metalloprotease inhibitors
|
US20050069918A1
(en)
|
2003-05-29 |
2005-03-31 |
Francois Claret |
JAB1 as a prognostic marker and a therapeutic target for human cancer
|
EP1661580B1
(en)
|
2003-07-25 |
2014-01-08 |
Ono Pharmaceutical Co., Ltd. |
Remedy for cartilage-related diseases
|
ES2754221T3
(es)
|
2003-08-29 |
2020-04-16 |
Ono Pharmaceutical Co |
Compuesto capaz de unirse al receptor de S1P y uso farmacéutico del mismo
|
CA2537355C
(en)
|
2003-09-01 |
2012-10-09 |
Ono Pharmaceutical Co., Ltd. |
Condensed ring compound and use thereof
|
US20080118442A1
(en)
*
|
2003-09-10 |
2008-05-22 |
Map Pharmaceuticals, Inc. |
Aerosol Formulations for Delivery of Dihydroergotamine to the Systemic Circulations Via Pulmonary Inhalation
|
WO2005041931A2
(en)
*
|
2003-10-20 |
2005-05-12 |
Schering Corporation |
Pharmaceutical aerosol compositions
|
WO2005063704A1
(ja)
|
2003-12-25 |
2005-07-14 |
Ono Pharmaceutical Co., Ltd. |
アゼチジン環化合物およびその医薬
|
WO2006004646A1
(en)
*
|
2004-06-28 |
2006-01-12 |
Nektar Therapeutics |
Aerosol formulation comprising nicotine salt
|
EP2465538A3
(en)
|
2004-10-21 |
2013-11-20 |
Ono Pharmaceutical Co., Ltd. |
Use of immunesuppressant receptor
|
ES2331619T3
(es)
*
|
2004-11-24 |
2010-01-11 |
Alcon, Inc. |
Procedimiento de administracion de spray nasal.
|
WO2006084041A2
(en)
|
2005-02-02 |
2006-08-10 |
Mitos Pharmaceuticals, Inc. |
Nitroxides for use in treating or preventing diabetes
|
JP5279487B2
(ja)
|
2005-05-18 |
2013-09-04 |
エムペックス・ファーマシューティカルズ・インコーポレーテッド |
エアロゾル化フルオロキノロンおよびその使用
|
US8524734B2
(en)
*
|
2005-05-18 |
2013-09-03 |
Mpex Pharmaceuticals, Inc. |
Aerosolized fluoroquinolones and uses thereof
|
EP1890732B1
(en)
|
2005-06-17 |
2018-03-28 |
Wisconsin Alumni Research Foundation |
Topical vasoconstrictor preparations and methods for protecting cells during cancer chemotherapy and radiotherapy
|
ES2427989T3
(es)
|
2005-10-28 |
2013-11-05 |
Ono Pharmaceutical Co., Ltd. |
Compuesto que contiene un grupo básico y uso del mismo
|
US20090281120A1
(en)
|
2005-12-12 |
2009-11-12 |
Ono Pharmaceutical Co., Ltd |
Bicyclic heterocyclic compound
|
JPWO2007069671A1
(ja)
|
2005-12-15 |
2009-05-21 |
小野薬品工業株式会社 |
二環式複素環化合物
|
US20070286814A1
(en)
*
|
2006-06-12 |
2007-12-13 |
Medispray Laboratories Pvt. Ltd. |
Stable aerosol pharmaceutical formulations
|
EP2425819A1
(en)
|
2007-02-11 |
2012-03-07 |
MAP Pharmaceuticals Inc |
Method of therapeutic administration of dhe to enable rapid relief of migraine while minimizing side effect profile
|
TW200902019A
(en)
|
2007-04-26 |
2009-01-16 |
Ono Pharmaceutical Co |
Dicyclic heterocyclic compound
|
DE102008007198A1
(de)
|
2008-02-01 |
2009-08-13 |
Infectopharm Arzneimittel Und Consilium Gmbh |
Oral oder nasal applizierbare Epinephrin- haltige Zubereitungen mit verbesserten Eigenschaften
|
LT2344129T
(lt)
|
2008-10-07 |
2018-05-10 |
Horizon Orphan Llc |
Aerozolinės fluorchinolono kompozicijos, skirtos farmakokinetikų pagerinimui
|
ES2809177T3
(es)
|
2008-10-07 |
2021-03-03 |
Horizon Orphan Llc |
Inhalación de levofloxacino para reducir la inflamación pulmonar
|
TWI469965B
(zh)
|
2008-12-22 |
2015-01-21 |
Ono Pharmaceutical Co |
乙炔基吲哚化合物
|
EP2444401B1
(en)
|
2009-06-17 |
2014-09-03 |
ONO Pharmaceutical Co., Ltd. |
Novel imidazopyridine compound
|
WO2010151804A1
(en)
*
|
2009-06-26 |
2010-12-29 |
Map Pharmaceuticals, Inc. |
Administration of dihydroergotamine mesylate particles using a metered dose inhaler
|
RU2563809C2
(ru)
|
2009-09-04 |
2015-09-20 |
Мпекс Фармасьютикалс, Инк. |
Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
|
WO2011066537A1
(en)
|
2009-11-30 |
2011-06-03 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide therapy for the treatment of von hippel - lindau disease (vhl) and renal clear cell carcinoma (rcc)
|
WO2011162222A1
(ja)
|
2010-06-21 |
2011-12-29 |
小野薬品工業株式会社 |
4,4'-[4-フルオロ-7-({4-[4-(3-フルオロ-2-メチルフェニル)ブトキシ]フェニル}エチニル)-2-メチル-1h-インドール-1,3-ジイル]ジブタン酸、4,4'-[2-メチル-7-({4-[4-(ペンタフルオロフェニル)ブトキシ]フェニル}エチニル)-1h-インドール-1,3-ジイル]ジブタン酸および4,4'-[4-フルオロ-2-メチル-7-({4-[4-(2,3,4,6-テトラフルオロフェニル)ブトキシ]フェニル}エチニル)-1h-インドール-1,3-ジイル]ジブタン酸の新規結晶形
|
US8748485B2
(en)
|
2010-12-02 |
2014-06-10 |
Ono Pharmaceuticals Co., Ltd. |
Compound and medical use thereof
|
EP2670242B1
(en)
|
2011-01-31 |
2022-03-16 |
Avalyn Pharma Inc. |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
WO2012127885A1
(ja)
|
2011-03-18 |
2012-09-27 |
小野薬品工業株式会社 |
テトラヒドロカルボリン誘導体
|
EP2842955B1
(en)
|
2012-04-26 |
2016-10-05 |
ONO Pharmaceutical Co., Ltd. |
Trk-inhibiting compound
|
HUE042591T2
(hu)
|
2013-02-19 |
2019-07-29 |
Ono Pharmaceutical Co |
TRK-gátló vegyület
|
US20150044288A1
(en)
|
2013-07-31 |
2015-02-12 |
Windward Pharma, Inc. |
Aerosol tyrosine kinase inhibitor compounds and uses thereof
|
NZ722927A
(en)
|
2014-01-10 |
2022-07-29 |
Avalyn Pharma Inc |
Aerosol pirfenidone and pyridone analog compounds and uses thereof
|
US10016439B2
(en)
|
2014-01-31 |
2018-07-10 |
Ono Pharmaceutical Co., Ltd. |
Fused imidazole compounds
|
US20200016255A1
(en)
|
2016-11-30 |
2020-01-16 |
Sumitomo Dainippon Pharma Co., Ltd. |
Wt1 helper peptides and combinations of wt1 helper peptide and conjugate of cancer antigen peptides
|
EP3604325A4
(en)
|
2017-03-30 |
2021-01-13 |
Sumitomo Dainippon Pharma Co., Ltd. |
WT1 CANCER ANTIGEN PEPTIDE AND PEPTIDE CONJUGATE BODY WITH IT
|
EP3679932A1
(en)
|
2017-09-06 |
2020-07-15 |
ONO Pharmaceutical Co., Ltd. |
METHOD FOR TREATING CANCER BY COMBINATION OF Trk INHIBITOR AND KINASE INHIBITOR
|
JP7388635B2
(ja)
|
2018-05-31 |
2023-11-29 |
小野薬品工業株式会社 |
免疫チェックポイント阻害薬の有効性判定バイオマーカー
|
CA3115749A1
(en)
|
2018-10-11 |
2020-04-16 |
Ono Pharmaceutical Co., Ltd. |
Sting agonistic compound
|
AU2020327251A1
(en)
|
2019-08-05 |
2022-03-03 |
National Cancer Center Japan |
Biomarker for accessing efficacy of immune checkpoint inhibitor
|
JPWO2021107125A1
(es)
|
2019-11-29 |
2021-06-03 |
|
|
EP4134134A4
(en)
|
2020-04-10 |
2023-12-27 |
ONO Pharmaceutical Co., Ltd. |
STING AGONIST COMPOUND
|
AU2021272616A1
(en)
|
2020-05-12 |
2022-12-15 |
International Institute Of Cancer Immunology, Inc. |
Pharmaceutical composition for treating cancer
|
WO2022240897A1
(en)
|
2021-05-10 |
2022-11-17 |
Sepelo Therapeutics, Llc |
Pharmaceutical composition comprising delafloxacin for administration into the lung
|
WO2022251679A1
(en)
|
2021-05-27 |
2022-12-01 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Nitroxide radicals for use as antiviral treatment for coronavirus infection
|
WO2023028364A1
(en)
|
2021-08-27 |
2023-03-02 |
Sepelo Therapeutics, Llc |
Targeted compositions and uses therof
|